ZVSA: שווי חברה לרווח נקי ZyVersa Therapeutics, Inc.

ZyVersa Therapeutics (ZVSA) is a biotech company developing treatments for nephrological pathologies and inflammation, whose success depends on inhibitor trials and partnerships. Production relies on outsourcing to certified US plants, which guarantees stable output. Patent protection creates a significant barrier to entry, although risks remain high until FDA approval. The current multiple is -0.20, which the asset value on the GURU.Markets platform clearly demonstrates.

ZyVersa Therapeutics (ZVSA) protects its positions with patents for kidney and metabolism treatment platforms under strict FDA oversight. The P/E ratio correlates the asset's market value with its actual net income, revealing the fundamental stability of the business. By analyzing the company's forward P/E, an investor determines the extent of the premium paid for future earnings. This metric distinguishes speculative growth from long-term value, allowing for an objective valuation of the biotech business.